Key result
The R90P mutation in Tpm3.12 caused abnormally high Ca2+-sensitivity and inhibited tropomyosin movement, effects that were weakened by the myosin ATPase inhibitor BDM and troponin C antagonist W7.
Why the study?
The molecular mechanisms underlying muscle dysfunction caused by the R90P mutation in gamma-tropomyosin (Tpm3.12) remain unclear.
BDM and W7 can mitigate the molecular defects in muscle contractility caused by the R90P mutation in γ-tropomyosin.
BDM and W7 merit further preclinical testing for R90P-related defects; hypothesis-generating in animal models and leaves open clinical translation.
Point mutations in the genes encoding the skeletal muscle isoforms of tropomyosin can cause a range of muscle diseases. The amino acid substitution of Arg for Pro residue in the 90th position (R90P) in γ-tropomyosin (Tpm3.12) is associated with congenital fiber type disproportion and muscle weakness. The molecular mechanisms underlying muscle dysfunction in this disease remain unclear. Here, we observed that this mutation causes an abnormally high Ca2+-sensitivity of myofilaments in vitro and in muscle fibers. To determine the critical conformational changes that myosin, actin, and tropomyosin undergo during the ATPase cycle and the alterations in these changes caused by R90P replacement in Tpm3.12, we used polarized fluorimetry. It was shown that the R90P mutation inhibits the ability of tropomyosin to shift towards the outer domains of actin, which is accompanied by the almost complete depression of troponin’s ability to switch actin monomers off and to reduce the amount of the myosin heads weakly bound to F-actin at a low Ca2+. These changes in the behavior of tropomyosin and the troponin–tropomyosin complex, as well as in the balance of strongly and weakly bound myosin heads in the ATPase cycle may underlie the occurrence of both abnormally high Ca2+-sensitivity and muscle weakness. BDM, an inhibitor of myosin ATPase activity, and W7, a troponin C antagonist, restore the ability of tropomyosin for Ca2+-dependent movement and the ability of the troponin–tropomyosin complex to switch actin monomers off, demonstrating a weakening of the damaging effect of the R90P mutation on muscle contractility.
No takes yet. Share an insight, caveat, or question.
Borovikov et al. (2021) studied Congenital fiber type disproportion and muscle weakness. BDM and W7 was evaluated on Conformational changes of myosin, actin, and tropomyosin during the ATPase cycle. The R90P mutation in Tpm3.12 caused abnormally high Ca2+-sensitivity and inhibited tropomyosin movement, effects that were weakened by the myosin ATPase inhibitor BDM and troponin C antagonist W7.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: